NO325532B1 - Pyrrolsubstituerte 2-indolinoner, farmasoytisk preparat omfattende slike, fremgangsmate for a modulere den katalytiske aktiviteten til en proteinkinase in vitro basert pa bruk av slike forbindelser, samt anvendelse av slike forbindelser til fremstilling av medikamenter for behandling av sykdommer. - Google Patents

Pyrrolsubstituerte 2-indolinoner, farmasoytisk preparat omfattende slike, fremgangsmate for a modulere den katalytiske aktiviteten til en proteinkinase in vitro basert pa bruk av slike forbindelser, samt anvendelse av slike forbindelser til fremstilling av medikamenter for behandling av sykdommer. Download PDF

Info

Publication number
NO325532B1
NO325532B1 NO20023831A NO20023831A NO325532B1 NO 325532 B1 NO325532 B1 NO 325532B1 NO 20023831 A NO20023831 A NO 20023831A NO 20023831 A NO20023831 A NO 20023831A NO 325532 B1 NO325532 B1 NO 325532B1
Authority
NO
Norway
Prior art keywords
compound
pyrrole
carboxylic acid
dimethyl
group
Prior art date
Application number
NO20023831A
Other languages
English (en)
Norwegian (no)
Other versions
NO20023831L (no
NO20023831D0 (no
Inventor
Peng Cho Tang
Chung Chen Wei
Todd A Miller
Li Xiaoyuan
Sun Li
Shahrzad Shirazian
Congxin Liang
Thomas Vojkovsky
Asaad D Nematalla
Michael Hawley
Original Assignee
Sugen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27391578&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO325532(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sugen Inc filed Critical Sugen Inc
Publication of NO20023831D0 publication Critical patent/NO20023831D0/no
Publication of NO20023831L publication Critical patent/NO20023831L/no
Publication of NO325532B1 publication Critical patent/NO325532B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Polyurethanes Or Polyureas (AREA)
NO20023831A 2000-02-15 2002-08-13 Pyrrolsubstituerte 2-indolinoner, farmasoytisk preparat omfattende slike, fremgangsmate for a modulere den katalytiske aktiviteten til en proteinkinase in vitro basert pa bruk av slike forbindelser, samt anvendelse av slike forbindelser til fremstilling av medikamenter for behandling av sykdommer. NO325532B1 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US18271000P 2000-02-15 2000-02-15
US21642200P 2000-07-06 2000-07-06
US24353200P 2000-10-27 2000-10-27
PCT/US2001/004813 WO2001060814A2 (en) 2000-02-15 2001-02-15 Pyrrole substituted 2-indolinone protein kinase inhibitors

Publications (3)

Publication Number Publication Date
NO20023831D0 NO20023831D0 (no) 2002-08-13
NO20023831L NO20023831L (no) 2002-10-15
NO325532B1 true NO325532B1 (no) 2008-06-09

Family

ID=27391578

Family Applications (4)

Application Number Title Priority Date Filing Date
NO20023831A NO325532B1 (no) 2000-02-15 2002-08-13 Pyrrolsubstituerte 2-indolinoner, farmasoytisk preparat omfattende slike, fremgangsmate for a modulere den katalytiske aktiviteten til en proteinkinase in vitro basert pa bruk av slike forbindelser, samt anvendelse av slike forbindelser til fremstilling av medikamenter for behandling av sykdommer.
NO2008019C NO2008019I2 (no) 2000-02-15 2008-12-08 Sunitinib
NO2010002C NO2010002I2 (no) 2000-02-15 2010-02-09 Toceranibfosfat.
NO2019005C NO2019005I1 (no) 2000-02-15 2019-02-05 N-[2-(dietylamino)etyl]-5-[(Z)-(5-fluoro-2-okso-1,2-dihydro-3H-indol-3-yliden)metyl]-2,4-dimetyl-1H-pyrrol-3-karboksamid (sunitinib), samt farmasøytisk akseptable salter

Family Applications After (3)

Application Number Title Priority Date Filing Date
NO2008019C NO2008019I2 (no) 2000-02-15 2008-12-08 Sunitinib
NO2010002C NO2010002I2 (no) 2000-02-15 2010-02-09 Toceranibfosfat.
NO2019005C NO2019005I1 (no) 2000-02-15 2019-02-05 N-[2-(dietylamino)etyl]-5-[(Z)-(5-fluoro-2-okso-1,2-dihydro-3H-indol-3-yliden)metyl]-2,4-dimetyl-1H-pyrrol-3-karboksamid (sunitinib), samt farmasøytisk akseptable salter

Country Status (42)

Country Link
US (4) US6573293B2 (cs)
EP (1) EP1255752B1 (cs)
JP (1) JP3663382B2 (cs)
KR (1) KR100713960B1 (cs)
CN (1) CN1329390C (cs)
AR (1) AR034118A1 (cs)
AT (1) ATE369359T1 (cs)
AU (2) AU3977001A (cs)
BE (1) BE2010C009I2 (cs)
BG (1) BG65764B1 (cs)
BR (2) BRPI0108394B8 (cs)
CA (1) CA2399358C (cs)
CO (1) CO5280092A1 (cs)
CR (2) CR20120007A (cs)
CY (3) CY1108032T1 (cs)
CZ (1) CZ303705B6 (cs)
DE (3) DE122010000004I1 (cs)
DK (1) DK1255752T3 (cs)
EA (1) EA005996B1 (cs)
ES (1) ES2290117T3 (cs)
FR (2) FR08C0002I2 (cs)
HR (1) HRP20020751B1 (cs)
HU (1) HU228979B1 (cs)
IL (1) IL151127A0 (cs)
IS (1) IS2491B (cs)
LT (1) LTC1255752I2 (cs)
LU (2) LU91407I2 (cs)
ME (1) ME00415B (cs)
MX (1) MXPA02008021A (cs)
MY (1) MY130363A (cs)
NL (2) NL300332I2 (cs)
NO (4) NO325532B1 (cs)
NZ (1) NZ520640A (cs)
PE (1) PE20011083A1 (cs)
PL (1) PL211834B1 (cs)
PT (1) PT1255752E (cs)
RS (1) RS50444B (cs)
SI (1) SI1255752T1 (cs)
SK (1) SK287142B6 (cs)
TW (1) TWI306860B (cs)
UA (1) UA73976C2 (cs)
WO (1) WO2001060814A2 (cs)

Families Citing this family (342)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569868B2 (en) 1998-04-16 2003-05-27 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
US20040226056A1 (en) * 1998-12-22 2004-11-11 Myriad Genetics, Incorporated Compositions and methods for treating neurological disorders and diseases
MXPA01007099A (es) 1999-01-13 2002-03-27 Univ New York State Res Found Metodo novedoso para disenar inhibidores de la proteina cinasa.
DK1255752T3 (da) 2000-02-15 2007-11-26 Sugen Inc Pyrrolsubstituerede 2-indolinonproteinkinaseinhibitorer
US7030219B2 (en) 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
TWI270545B (en) 2000-05-24 2007-01-11 Sugen Inc Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
CA2410509A1 (en) 2000-06-02 2001-12-13 Sugen, Inc. Indolinone derivatives as protein kinase/phosphatase inhibitors
US6635640B2 (en) 2000-06-30 2003-10-21 Sugen, Inc. 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
DE60134679D1 (de) 2000-10-20 2008-08-14 Eisai R&D Man Co Ltd Stickstoff enthaltende aromatische Heterozyklen
WO2002055517A2 (en) * 2000-12-20 2002-07-18 Jingrong Cui 4-(hetero)aryl substituted indolinones
AR042586A1 (es) * 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
EP1370527A1 (en) 2001-03-06 2003-12-17 AstraZeneca AB Indolone derivatives having vascular-damaging activity
EP1247809A3 (en) * 2001-03-30 2003-12-17 Pfizer Products Inc. Triazine compounds useful as sorbitol dehydrogenase inhibitors
PE20030062A1 (es) 2001-05-30 2003-02-08 Sugen Inc Derivados aralquilsulfonil-3-(pirrol-2-ilmetiliden)-2-indolinona como inhibidores de quinasas
CA2452361A1 (en) * 2001-06-29 2003-01-09 Ab Science Use of tyrosine kinase inhibitors for treating autoimmune diseases
AP1660A (en) 2001-08-15 2006-09-09 Upjohn Co Crystals including a malic acid salt of N - [2 -(diethylamino) ethyl] - 5 - [ (5 - fluoro -2-oxo - 3H -indole -3 - ylidene) methyl] - 2,4 - dimethyl - 1H- pyrrole -3 -carboxamide, processes for its preparation and compositions thereof.
AR038957A1 (es) * 2001-08-15 2005-02-02 Pharmacia Corp Terapia de combinacion para el tratamiento del cancer
WO2003022815A1 (en) * 2001-09-10 2003-03-20 Sugen, Inc. 3-(4,5,6,7-tetrahydroindol-2-ylmethylidiene)-2-indolinone derivatives as kinase inhibitors
CA2462950A1 (en) * 2001-10-10 2003-04-17 Sugen, Inc. 3-[4-(substituted heterocyclyl)-pyrrol-2-ylmethylidene]-2-indolinone derivatives as kinase inhibitors
US7005445B2 (en) 2001-10-22 2006-02-28 The Research Foundation Of State University Of New York Protein kinase and phosphatase inhibitors and methods for designing them
CA2464214C (en) * 2001-10-22 2011-02-08 The Research Foundation Of State University Of New York Protein kinase and phosphatase inhibitors, methods for designing them, and methods of using them
TWI259081B (en) * 2001-10-26 2006-08-01 Sugen Inc Treatment of acute myeloid leukemia with indolinone compounds
US20030080191A1 (en) * 2001-10-26 2003-05-01 Allen Lubow Method and apparatus for applying bar code information to products during production
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
US6797825B2 (en) 2001-12-13 2004-09-28 Abbott Laboratories Protein kinase inhibitors
US20050131733A1 (en) * 2001-12-17 2005-06-16 Allen Lubow Sealable individual bar coded packets
WO2003052681A1 (en) * 2001-12-17 2003-06-26 International Barcode Corporation Double-sided bar code doubling as a single bar code
DK1458713T3 (da) * 2001-12-27 2005-10-31 Theravance Inc Indolinonderivater anvendelige som proteinkinaseinhibitorer
CN1308326C (zh) * 2002-02-15 2007-04-04 法马西亚和厄普乔恩公司 吲哚满酮衍生物的制备方法
WO2003097854A2 (en) * 2002-05-17 2003-11-27 Sugen, Inc. Novel biomarkers of tyrosine kinase inhibitor exposure and activity in mammals
ITMI20021620A1 (it) * 2002-07-23 2004-01-23 Novuspharma Spa Composto ad ativita' antitumorale
WO2004016211A2 (en) * 2002-08-08 2004-02-26 Vanderbilt University Pi3k antagonists as radiosensitizers
EP1576129A4 (en) * 2002-08-09 2008-01-23 Theravance Inc ONCOKINASE FUSION POLYPEPTIDES ASSOCIATED WITH HYPERPROLIFERATIVE DISORDERS, NUCLEIC ACIDS ENCODING THESE POLYPEPTIDES AND METHODS OF DETECTION AND IDENTIFICATION THEREOF
US20040121407A1 (en) * 2002-09-06 2004-06-24 Elixir Pharmaceuticals, Inc. Regulation of the growth hormone/IGF-1 axis
HN2003000272A (es) * 2002-09-10 2008-07-29 Pharmacia Italia Spa Formulaciones que comprenden un compuesto de indolinona
EP1581309A4 (en) * 2002-11-15 2009-07-29 Exelixis Inc KINASE MODULATORS
AR042042A1 (es) * 2002-11-15 2005-06-08 Sugen Inc Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celular
US20040209937A1 (en) * 2003-02-24 2004-10-21 Sugen, Inc. Treatment of excessive osteolysis with indolinone compounds
US7452913B2 (en) * 2003-02-24 2008-11-18 Pharmacia & Upjohn Company Polymorphs of pyrrole substituted 2-indolinone protein kinase inhibitors
ES2502490T3 (es) 2003-02-26 2014-10-03 Sugen, Inc. Compuestos aminoheteroarílicos como inhibidores de proteín quinasas
US20040266843A1 (en) * 2003-03-07 2004-12-30 Sugen, Inc. Sulfonamide substituted indolinones as inhibitors of DNA dependent protein kinase (DNA-PK)
US7157577B2 (en) * 2003-03-07 2007-01-02 Sugen Inc. 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors
WO2004080462A1 (ja) * 2003-03-10 2004-09-23 Eisai Co., Ltd. c-Kitキナーゼ阻害剤
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
DE10334582A1 (de) * 2003-07-28 2005-02-24 Basf Ag Verfahren zur Herstellung von Maleinsäureanhydrid
WO2005023765A1 (en) * 2003-09-11 2005-03-17 Pharmacia & Upjohn Company Llc Method for catalyzing amidation reactions by the presence of co2
ATE473223T1 (de) * 2003-10-02 2010-07-15 Pharmacia & Upjohn Co Llc Salze und polymorphe formen einer pyrrolsubstituierten indolinonverbindung
PL1680140T3 (pl) * 2003-10-16 2011-11-30 Imclone Llc Inhibitory receptora-1 czynnika wzrostu fibroblastów i związane z nim sposoby leczenia
EP1682529A4 (en) 2003-11-07 2010-06-30 Novartis Vaccines & Diagnostic PROCESS FOR SYNTHESIS OF CHINOLINONE COMPOUNDS
CN101337930B (zh) 2003-11-11 2010-09-08 卫材R&D管理有限公司 脲衍生物的制备方法
CA2547066A1 (en) * 2003-11-26 2005-06-16 The Scripps Research Institute Advanced indolinone based protein kinase inhibitors
EP1699477A2 (en) * 2003-12-11 2006-09-13 Theravance, Inc. Compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
US20050152943A1 (en) * 2003-12-23 2005-07-14 Medtronic Vascular, Inc. Medical devices to treat or inhibit restenosis
WO2005118543A1 (ja) * 2004-06-03 2005-12-15 Ono Pharmaceutical Co., Ltd. キナーゼ阻害薬およびその用途
CA2571421A1 (en) 2004-06-24 2006-01-05 Nicholas Valiante Compounds for immunopotentiation
SE0401790D0 (sv) * 2004-07-07 2004-07-07 Forskarpatent I Syd Ab Tamoxifen response in pre- and postmenopausal breast cancer patients
US20060009510A1 (en) * 2004-07-09 2006-01-12 Pharmacia & Upjohn Company Llc Method of synthesizing indolinone compounds
NZ552866A (en) * 2004-08-26 2010-06-25 Pfizer Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
DE602005013990D1 (de) 2004-09-17 2009-05-28 Eisai R&D Man Co Ltd Medizinische zusammensetzung mit verbesserter stabilität und reduzierten gelierungseigenschaften
CN100432071C (zh) * 2004-11-05 2008-11-12 中国科学院上海药物研究所 取代1h－吲哚－2－酮类化合物及其制备方法和用途
GT200500321A (es) 2004-11-09 2006-09-04 Compuestos y composiciones como inhibidores de proteina kinase.
US20090074787A1 (en) * 2005-03-23 2009-03-19 Pfizer, Inc., Pfizer Products, Inc. Anti-CTLA4 Antibody and Indolinone Combination Therapy for Treatment of Cancer
WO2006114704A2 (en) 2005-04-26 2006-11-02 Pfizer Inc. P-cadherin antibodies
AU2006245421A1 (en) * 2005-05-12 2006-11-16 Pfizer Inc. Anticancer combination therapy using sunitinib malate
TWI441637B (zh) 2005-05-18 2014-06-21 Array Biopharma Inc Ｍｅｋ雜環抑制劑及其使用方法
BRPI0611375A2 (pt) 2005-05-23 2010-08-31 Novartis Ag formas cristalinas e outras de sais de ácido láctico de 4-amino-5-flúor-3-[6-(4-metilpiperazin-1-il)-1h-benzimid azol-2-il]-1h-quinolin-2-ona
MX2007014810A (es) * 2005-05-26 2008-02-21 Scripps Research Inst Inhibidores de la proteina quinasa mejoradas a base de indolinona.
US20100105031A1 (en) * 2005-08-01 2010-04-29 Esai R & D Management Co., Ltd. Method for prediction of the efficacy of vascularization inhibitor
JP4989476B2 (ja) 2005-08-02 2012-08-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質の効果を検定する方法
ME00501B (me) 2005-09-07 2011-10-10 Pfizer Humana monoklonska antitijela na kinazu 1 sličnu aktivnom receptoru
PL1928858T3 (pl) * 2005-09-19 2009-12-31 Zoetis Services Llc Stałe postacie soli pirolo-podstawionego 2-indolinonu
WO2007052849A1 (ja) 2005-11-07 2007-05-10 Eisai R & D Management Co., Ltd. 血管新生阻害物質とc-kitキナーゼ阻害物質との併用
UA96139C2 (uk) 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)
US20080269212A1 (en) * 2005-12-29 2008-10-30 The Scripps Research Institute Amino acid derivatives of indolinone based protein kinase inhibitors
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
CN101007801A (zh) * 2006-01-27 2007-08-01 上海恒瑞医药有限公司 吡咯取代的2－二氢吲哚酮衍生物、其制法与医药上的用途
TW200808739A (en) 2006-04-06 2008-02-16 Novartis Vaccines & Diagnostic Quinazolines for PDK1 inhibition
TW200813091A (en) 2006-04-10 2008-03-16 Amgen Fremont Inc Targeted binding agents directed to uPAR and uses thereof
CN101472915A (zh) 2006-04-19 2009-07-01 诺瓦提斯公司 吲唑化合物和抑制cdc7的方法
EP2258700A1 (en) 2006-05-09 2010-12-08 Pfizer Products Inc. Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
US20090209580A1 (en) 2006-05-18 2009-08-20 Eisai R & D Management Co., Ltd. Antitumor agent for thyroid cancer
DE102006024834B4 (de) * 2006-05-24 2010-07-01 Schebo Biotech Ag Neue Indol-Pyrrol-Derivate und deren Verwendungen
US7838542B2 (en) 2006-06-29 2010-11-23 Kinex Pharmaceuticals, Llc Bicyclic compositions and methods for modulating a kinase cascade
EP2044939A1 (en) * 2006-06-29 2009-04-08 Eisai R&D Management Co., Ltd. Therapeutic agent for liver fibrosis
AU2007272330A1 (en) 2006-07-13 2008-01-17 Zymogenetics, Inc. Interleukin 21 and tyrosine kinase inhibitor combination therapy
CL2007002225A1 (es) 2006-08-03 2008-04-18 Astrazeneca Ab Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
JP5238697B2 (ja) 2006-08-04 2013-07-17 武田薬品工業株式会社 縮合複素環誘導体およびその用途
HRP20170627T1 (hr) 2006-08-23 2017-06-30 Kudos Pharmaceuticals Limited Derivati 2-metilmorfolin pirido-, pirazo- i pirimido-pirimidina kao inhibitori mtor
CN101511793B (zh) * 2006-08-28 2011-08-03 卫材R&D管理有限公司 针对未分化型胃癌的抗肿瘤剂
EP2079727B1 (en) 2006-09-15 2016-02-17 Xcovery, INC. Kinase inhibitor compounds
EP2087001B1 (en) 2006-11-02 2016-10-26 Acceleron Pharma, Inc. Alk1 receptor and ligand antagonists and uses thereof
CN101600718B (zh) 2006-11-06 2013-07-03 特雷罗药物股份有限公司 咪唑并[1,2-b]哒嗪和吡唑并[1,5-a]嘧啶衍生物及其作为蛋白激酶抑制剂的用途
JP4623604B2 (ja) * 2006-11-06 2011-02-02 株式会社セラバリューズ 新規なオキシインドール誘導体
JP5542445B2 (ja) 2006-12-04 2014-07-09 江▲蘇▼先声▲薬▼物研究有限公司 ３−ピロロシクロへキシリデン−２−ジヒドロインドリノン誘導体およびその用途
CN101600694A (zh) 2007-01-29 2009-12-09 卫材R&D管理有限公司 未分化型胃癌治疗用组合物
EA200970669A1 (ru) 2007-02-06 2010-02-26 Пфайзер Инк. Производные 2-амино-5,7-дигидро-6н-пирроло[3,4-d]пиримидина в качестве ингибиторов hsp-90, предназначенные для лечения рака
JPWO2008114819A1 (ja) 2007-03-20 2010-07-08 大日本住友製薬株式会社 新規アデニン化合物
US20090004213A1 (en) 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
US20090042906A1 (en) * 2007-04-26 2009-02-12 Massachusetts Institute Of Technology Methods for treating cancers associated with constitutive egfr signaling
WO2008138184A1 (fr) 2007-05-14 2008-11-20 Shanghai Hengrui Pharmaceutical Co.Ltd. Dérivés de pyrrolo-azacycles, leur procédé de fabrication et leur utilisation en tant qu'inhibiteurs de protéine kinases
WO2008145398A1 (en) * 2007-06-01 2008-12-04 Pfizer Italia S.R.L. 4-arylpyrrole substituted 2-indoline derivatives active as protein kinase inhibitors
JP5352476B2 (ja) 2007-06-05 2013-11-27 武田薬品工業株式会社 キナーゼ阻害剤としての二環式複素環化合物
EP2181987B9 (en) 2007-08-23 2014-09-03 Takeda Pharmaceutical Company Limited 2-Carbonylaminobenzothiazoles and their use for the prophylaxis and treatment of cancer
US20090062368A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched sunitinib
HUE030774T2 (hu) 2007-09-06 2017-05-29 Boston Biomedical Inc Kinázinhibitorokból álló készítmények és felhasználásuk a rák és a kinázokhoz kapcsolódó más betegségek kezelésére
AU2008309383B2 (en) 2007-10-11 2012-04-19 Astrazeneca Ab Pyrrolo [2, 3 -D] pyrimidin derivatives as protein kinase B inhibitors
KR101513326B1 (ko) 2007-11-09 2015-04-17 에자이 알앤드디 매니지먼트 가부시키가이샤 혈관 신생 저해 물질과 항종양성 백금 착물의 병용
US20100256392A1 (en) * 2007-11-21 2010-10-07 Teva Pharmaceutical Industries Ltd. Polymorphs of sunitinib base and processes for preparation thereof
WO2009067686A2 (en) * 2007-11-21 2009-05-28 Teva Pharmaceutical Industries Ltd. Sunitinib hemi-l-malate, polymorphs and preparation thereof, polymorphs of racemic sunitinib malate, compositins containing sunitinib base and malic acid and preparation thereof
CA2709083A1 (en) * 2007-12-12 2009-06-18 Medichem S.A. Polymorphic forms of a 3-pyrrole substituted 2-indolinone
PT2222675E (pt) 2007-12-19 2013-11-13 Genentech Inc 5-anilinoimidazopiridinas e métodos de utilização
US8940771B2 (en) 2007-12-20 2015-01-27 Novartis Ag Organic compounds
US8486963B2 (en) 2007-12-21 2013-07-16 Genentech, Inc. Azaindolizines and methods of use
KR101506062B1 (ko) * 2008-01-29 2015-03-25 에자이 알앤드디 매니지먼트 가부시키가이샤 혈관 저해 물질과 탁산의 병용
EP2090306A1 (en) 2008-02-13 2009-08-19 Ratiopharm GmbH Pharmaceutical compositions comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
EP2113248A1 (en) 2008-04-29 2009-11-04 Ratiopharm GmbH Pharmaceutical composition comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-,4-dimethyl-1H-pyrrole-3-carboxamide
CA2713112A1 (en) * 2008-02-13 2009-08-20 Ratiopharm Gmbh Pharmaceutical compositions comprising n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide
CN101255154B (zh) * 2008-02-18 2011-09-07 靳广毅 一种取代的2-吲哚啉酮衍生物和制备方法及其应用
CN101983195A (zh) * 2008-02-21 2011-03-02 基因里克斯(英国)有限公司 新型多晶型物及其制备方法
EP2098521A1 (en) * 2008-03-06 2009-09-09 Ratiopharm GmbH Crystal forms of N-[2-(diethylamino) ethyl]-5-[fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrolle-3-carboxamide and methods for their prepparation
WO2009124037A1 (en) * 2008-03-31 2009-10-08 Teva Pharmaceutical Industries Ltd. Processes for preparing sunitinib and salts thereof
CA2720943A1 (en) * 2008-04-16 2009-10-22 Natco Pharma Limited Novel polymorphic forms of sunitinib base
US8158656B2 (en) * 2008-05-16 2012-04-17 Shenzhen Chipscreen Biosciences Ltd. 2-indolinone derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors
EP2292613B1 (en) * 2008-05-23 2015-09-30 Shanghai Institute of Pharmaceutical Industry Dihydroindolinone derivatives
US8263547B2 (en) 2008-05-28 2012-09-11 Massachusetts Institute Of Technology DISC-1 pathway activators in the control of neurogenesis
EP2313371B1 (en) * 2008-06-13 2012-08-15 Medichem, S.A. Process for preparing a 3-pyrrole substituted 2-indolinone malate salt
US8501962B2 (en) 2008-06-23 2013-08-06 Natco Pharma Limited Process for the preparation of high purity sunitinib and its pharmaceutically acceptable salt
EP2138167A1 (en) 2008-06-24 2009-12-30 ratiopharm GmbH Pharmaceutical composition comprising N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
WO2009156837A2 (en) * 2008-06-26 2009-12-30 Medichem, S.A. Amorphous form of a 3-pyrrole substituted 2-indolinone malate salt
EP2294184A4 (en) 2008-06-30 2013-03-06 Mesoblast Inc TREATMENT OF EYE DISEASES AND EXCESSIVE NEOVASCULARIZATION WITH THE HELP OF COMBINED THERAPY
DE102008031038A1 (de) 2008-06-30 2009-12-31 Alexander Priv.-Doz. Dr. Dömling Sutent zur Anwendung in der Organtransplantation
WO2010002933A1 (en) * 2008-06-30 2010-01-07 Cylene Pharmaceuticals, Inc. Oxindole compounds
CA2729253A1 (en) * 2008-07-02 2010-01-07 Generics [Uk] Limited Novel process
US20110257237A1 (en) * 2008-07-10 2011-10-20 Generics [Uk] Limited Process for the preparation of crystalline forms of sunitinib malate
CN102164913A (zh) 2008-07-24 2011-08-24 麦迪凯姆股份公司 一种3-吡咯替代的2-吲哚酮苹果酸盐的结晶体形式
WO2010011834A2 (en) 2008-07-24 2010-01-28 Teva Pharmaceutical Industries Ltd. Sunitinib and salts thereof and their polymorphs
WO2010017541A2 (en) * 2008-08-08 2010-02-11 The Johns Hopkins University Compositions and methods for treatment of neurodegenerative disease
JP2012500838A (ja) * 2008-08-25 2012-01-12 ジェネリクス・（ユーケー）・リミテッド スニチニブの新規な多形およびその調製方法
CN102197035A (zh) * 2008-08-25 2011-09-21 基因里克斯(英国)有限公司 舒尼替尼的结晶形式及其制备方法
DK2350129T3 (en) 2008-08-25 2015-08-31 Amplimmune Inc PREPARATIONS WITH PD-1 ANTAGONISTS AND PROCEDURES FOR USE THEREOF
CA2735006A1 (en) * 2008-08-25 2010-03-11 Amplimmune, Inc. Pd-1 antagonists and methods of use thereof
KR20110066927A (ko) * 2008-09-05 2011-06-17 임페리얼 이노베이션스 리미티드 생체 내 영상화제로서 사용하기 위한 이사틴 유도체
AU2009294415B2 (en) 2008-09-19 2015-09-24 Medimmune Llc Antibodies directed to DLL4 and uses thereof
CN102177155A (zh) * 2008-10-10 2011-09-07 麦迪凯姆股份公司 一种3-吡咯取代的2-吲哚酮苹果酸盐的制备工艺
EP2181991A1 (en) * 2008-10-28 2010-05-05 LEK Pharmaceuticals D.D. Novel salts of sunitinib
EP2186809A1 (en) * 2008-11-13 2010-05-19 LEK Pharmaceuticals D.D. New crystal form of sunitinib malate
US20100222371A1 (en) * 2008-11-20 2010-09-02 Children's Medical Center Corporation Prevention of surgical adhesions
EP2399921B1 (en) 2008-12-01 2015-08-12 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
JO3101B1 (ar) 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co مشتقات بنزوثيازول كعوامل مضادة للسرطان
TW201028410A (en) 2008-12-22 2010-08-01 Astrazeneca Ab Chemical compounds 610
US20120114667A1 (en) 2008-12-23 2012-05-10 Medimmune Limited TARGETED BINDING AGENTS DIRECTED TO a5BETA1 AND USES THEREOF
EP2896618A1 (en) 2009-01-02 2015-07-22 Hetero Research Foundation Polymorphs of sunitinib malate
KR102187034B1 (ko) 2009-01-16 2020-12-04 엑셀리시스, 인코포레이티드 암 치료용 ｎ-（４-｛〔６，７-비스（메틸옥시）퀴놀린-4-일〕옥시｝페닐）-ｎ＇-（４-플루오로페닐）사이클로프로판-1,1-디카르복사미드의 말산염 및 그 결정형
EP3100745B1 (en) 2009-02-05 2018-04-18 Immunogen, Inc. Novel benzodiazepine derivatives
CA2748943A1 (en) 2009-02-09 2010-08-12 Supergen, Inc. Pyrrolopyrimidinyl axl kinase inhibitors
US9265764B2 (en) * 2009-02-27 2016-02-23 Massachusetts Institute Of Technology Uses of chemicals to modulate GSK-3 signaling for treatment of bipolar disorder and other brain disorders
WO2010098866A1 (en) 2009-02-27 2010-09-02 Supergen, Inc. Cyclopentathiophene/cyclohexathiophene dna methyltransferase inhibitors
US8785457B2 (en) 2009-03-13 2014-07-22 Cellzome Limited Pyrimidine derivatives as mTOR inhibitors
WO2010108503A1 (en) 2009-03-24 2010-09-30 Life & Brain Gmbh Promotion of neuronal integration in neural stem cell grafts
WO2010118986A1 (en) 2009-04-14 2010-10-21 Cellzome Limited Fluoro substituted pyrimidine compounds as jak3 inhibitors
US8530492B2 (en) 2009-04-17 2013-09-10 Nektar Therapeutics Oligomer-protein tyrosine kinase inhibitor conjugates
EP2255792A1 (en) 2009-05-20 2010-12-01 Ratiopharm GmbH Pharmaceutical compositions for N-[2-(Diethylamino)ethyl]5-[(fluoro-1,2-dihydro-2-oxo-3H-indole-3-ylidene) methyl]-2,4-dimenthyl-1H-pyrrole-3-carboxamide
US8211901B2 (en) 2009-05-22 2012-07-03 Shenzhen Chipscreen Biosciences Ltd. Naphthamide derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors
EP2264027A1 (en) 2009-05-27 2010-12-22 Ratiopharm GmbH Process for the preparation of N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
US8389580B2 (en) 2009-06-02 2013-03-05 Duke University Arylcyclopropylamines and methods of use
CN101906076B (zh) 2009-06-04 2013-03-13 深圳微芯生物科技有限责任公司 作为蛋白激酶抑制剂和组蛋白去乙酰化酶抑制剂的萘酰胺衍生物、其制备方法及应用
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
WO2011004200A1 (en) 2009-07-10 2011-01-13 Generics [Uk] Limited Novel pyrrole derivatives
FR2948940B1 (fr) 2009-08-04 2011-07-22 Servier Lab Nouveaux derives dihydroindolones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2011029807A1 (en) 2009-09-11 2011-03-17 Cellzome Limited Ortho substituted pyrimidine compounds as jak inhibitors
US20120220783A1 (en) 2009-09-16 2012-08-30 Ranbaxy Laboratories Limited Salts of sunitinib
US9242987B2 (en) 2009-10-20 2016-01-26 Cellzome Limited Heterocyclyl pyrazolopyrimidine analogues as JAK inhibitors
EP2499133A2 (en) 2009-11-12 2012-09-19 Ranbaxy Laboratories Limited Process for the preparation of crystalline form i of l-malic acid salt of sunitinib
WO2011061613A1 (en) 2009-11-19 2011-05-26 Ranbaxy Laboratories Limited Process for the preparation of crystalline form ii of l-malic acid salt of sunitinib
KR101934071B1 (ko) 2009-11-24 2019-01-02 메디뮨 리미티드 Ｂ７―ｈ１에 대한 표적화된 결합 물질
EP2507237A1 (en) 2009-12-03 2012-10-10 Dainippon Sumitomo Pharma Co., Ltd. Imidazoquinolines which act via toll - like receptors (tlr)
WO2013022801A1 (en) 2011-08-05 2013-02-14 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
WO2011095802A1 (en) 2010-02-02 2011-08-11 Generics [Uk] Limited Hplc method for analyzing sunitinib
WO2011100325A2 (en) * 2010-02-09 2011-08-18 Sicor Inc. Polymorphs of sunitinib salts
WO2011100403A1 (en) 2010-02-10 2011-08-18 Immunogen, Inc Cd20 antibodies and uses thereof
KR101498774B1 (ko) 2010-02-22 2015-03-04 에프. 호프만-라 로슈 아게 피리도［3,2-ｄ］피리미딘 ｐｉ3ｋ 델타 억제제 화합물 및 이의 용도
WO2011104555A2 (en) * 2010-02-25 2011-09-01 Generics [Uk] Limited Novel process
ES2535116T3 (es) 2010-03-04 2015-05-05 Cellzome Limited Derivados de urea sustituida con morfolino como inhibidores de mtor
WO2011107919A1 (en) 2010-03-04 2011-09-09 Ranbaxy Laboratories Limited Process for the direct preparation of malic acid salt of sunitinib
EP2545034A1 (en) * 2010-03-10 2013-01-16 Synthon B.V. A process for amidation of pyrrole carboxylate compounds
WO2011114246A1 (en) 2010-03-18 2011-09-22 Ranbaxy Laboratories Limited Process for the preparation of malic acid salt of sunitinib
US9162981B2 (en) 2010-03-23 2015-10-20 The Johns Hopkins University Compositions and methods for treatment of neurodegenerative disease
WO2011128699A2 (en) * 2010-04-16 2011-10-20 Generics [Uk] Limited Novel process
EP2566867A1 (en) 2010-04-30 2013-03-13 Cellzome Limited Pyrazole compounds as jak inhibitors
WO2011138565A1 (fr) 2010-05-05 2011-11-10 Biorebus Association pharmaceutique contenant l'acide lipoïque, l'acide hydroxycitrique et une somatostatine a titre de principes actifs
EP2392324A1 (en) 2010-06-01 2011-12-07 Societe De Coordination De Recherches Therapeutiques Rhenium complexes and their pharmaceutical use
SA111320519B1 (ar) 2010-06-11 2014-07-02 Astrazeneca Ab مركبات بيريميدينيل للاستخدام كمثبطات atr
RU2560683C2 (ru) 2010-06-25 2015-08-20 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противоопухолевое средство, задействующее соединения с ингибирующим эффектом к киназам в комбинации
US20130143915A1 (en) 2010-07-01 2013-06-06 Cellzome Limited Triazolopyridines as tyk2 inhibitors
BR112013000340A2 (pt) 2010-07-09 2016-05-31 Genentech Inc anticorpo isolado que se liga a neuropilina-1 (nrp1), ácido nucleico isolado, célula hospedeira, método de produção de um anticorpo, imunoconjugado e método de detecção da presença de nrp1 em uma amostra biológica
AR082418A1 (es) 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
US9040545B2 (en) 2010-08-20 2015-05-26 Cellzome Limited Heterocyclyl pyrazolopyrimidine analogues as selective JAK inhibitors
WO2012027716A1 (en) 2010-08-27 2012-03-01 Collabrx, Inc. Method to treat melanoma in braf inhibitor-resistant subjects
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
BR112013010920A2 (pt) 2010-11-01 2016-07-12 Scinopharm Kunshan Biochemical Technology Co Ltd processos para a preparação de 3 - ((pirrol-2-il)metileno)-2-pirrolonas utilizando 2-sillixa-pirrolas
WO2012059941A1 (en) * 2010-11-04 2012-05-10 Ind-Swift Laboratories Limited Process for preparation of sunitinib malate and salts thereof
AU2011328237A1 (en) 2010-11-09 2013-05-23 Cellzome Limited Pyridine compounds and aza analogues thereof as TYK2 inhibitors
WO2012068487A1 (en) 2010-11-18 2012-05-24 Synta Pharmaceuticals Corp. Preselection of subjects for therapeutic treatment with oxygen sensitive agents based on hypoxic status
WO2012068549A2 (en) 2010-11-19 2012-05-24 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
TWI410425B (zh) 2010-12-03 2013-10-01 Lilly Co Eli 唑并［５，４－ｂ］吡啶－５－基化合物
JP6002149B2 (ja) 2010-12-23 2016-10-05 ネクター セラピューティクス ポリマー−スニチニブコンジュゲート
US10220020B2 (en) 2010-12-23 2019-03-05 Nektar Therapeutics Polymer-des-ethyl sunitinib conjugates
PE20140293A1 (es) 2011-01-31 2014-03-19 Novartis Ag Novedosos derivados heterociclicos
IL293365A (en) 2011-02-15 2022-07-01 Immunogen Inc Cytotoxic benzodiazepine derivatives, compositions comprising the same and uses thereof
CN103534240B (zh) 2011-02-17 2015-12-09 癌症疗法Crc私人有限公司 选择性fak抑制剂
JP5937111B2 (ja) 2011-02-17 2016-06-22 カンサー・セラピューティクス・シーアールシー・プロプライエタリー・リミテッドＣａｎｃｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｃｒｃ Ｐｔｙ Ｌｉｍｉｔｅｄ Ｆａｋ阻害剤
GB201103578D0 (en) 2011-03-02 2011-04-13 Sabrepharm Ltd Dipyridinium derivatives
US8630703B2 (en) 2011-03-09 2014-01-14 Technion Research & Development Foundation Limited Treatment utilizing hydrophobic weak bases chemotherapeutic agents and illumination
CN102115469A (zh) * 2011-03-21 2011-07-06 浙江大学 吲哚啉-2-酮类衍生物的制备和用途
JP2014510122A (ja) 2011-04-04 2014-04-24 セルゾーム リミテッド ｍＴＯＲ阻害剤としてのジヒドロピロロピリミジン誘導体
AU2012240018A1 (en) 2011-04-08 2013-10-10 Beta Pharma, Inc. New indolinone protein kinase inhibitors
WO2012143320A1 (en) 2011-04-18 2012-10-26 Cellzome Limited (7h-pyrrolo[2,3-d]pyrimidin-2-yl)amine compounds as jak3 inhibitors
KR101762999B1 (ko) 2011-04-18 2017-07-28 에자이 알앤드디 매니지먼트 가부시키가이샤 종양 치료제
CN102898402B (zh) * 2011-04-26 2016-01-20 北京大学 一种苯并异硒唑酮修饰的吡咯甲酸酯取代的吲哚酮类化合物及其应用
ES2841809T3 (es) 2011-06-03 2021-07-09 Eisai R&D Man Co Ltd Biomarcadores para pronosticar y evaluar el grado de respuesta de sujetos con cáncer de tiroides y de riñón a compuestos de lenvatinib
EP3812387A1 (en) 2011-07-21 2021-04-28 Sumitomo Dainippon Pharma Oncology, Inc. Heterocyclic protein kinase inhibitors
US20140179664A1 (en) 2011-07-28 2014-06-26 Cellzome Limited Heterocyclyl Pyrimidine Analogues As JAK Inhibitors
WO2013017480A1 (en) 2011-07-29 2013-02-07 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
WO2013017479A1 (en) 2011-07-29 2013-02-07 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
EP2760863A1 (en) 2011-09-20 2014-08-06 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as kinase inhibitors
WO2013041652A1 (en) 2011-09-21 2013-03-28 Cellzome Limited Morpholino substituted urea or carbamate derivatives as mtor inhibitors
AU2012320465B2 (en) 2011-10-07 2016-03-03 Cellzome Limited Morpholino substituted bicyclic pyrimidine urea or carbamate derivatives as mTOR inhibitors
CN102499917B (zh) 2011-10-25 2014-12-17 澳门大学 吲哚酮类化合物在制备神经保护药物中的应用
PT2771342T (pt) 2011-10-28 2016-08-17 Novartis Ag Derivados de purina e o seu uso no tratamento de doença
CN103130774B (zh) * 2011-11-22 2016-06-22 齐鲁制药有限公司 具有酪氨酸激酶抑制作用的化合物及其制备方法和应用
CN103127096B (zh) * 2011-12-02 2015-11-25 杨子娇 吡咯基取代的吲哚类化合物在治疗青光眼病的应用
AU2012357038B2 (en) 2011-12-23 2016-05-12 Cellzome Limited Pyrimidine-2,4-diamine derivatives as kinase inhibitors
US20130178520A1 (en) 2011-12-23 2013-07-11 Duke University Methods of treatment using arylcyclopropylamine compounds
CN102491932A (zh) * 2011-12-26 2012-06-13 天津科技大学 一种3-吲哚啉酮类衍生物及其制备方法及其应用
CN104114550A (zh) 2012-03-23 2014-10-22 劳拉斯实验室私人有限公司 制备舒尼替尼及其酸加成盐的改进的方法
IN2014MN02105A (cs) 2012-04-20 2015-09-11 Annji Pharm Co Ltd
CN102653521B (zh) * 2012-04-27 2014-08-06 首都师范大学 吲哚-2-酮的哌嗪硫代甲酰肼衍生物及其制备方法和用途
PL399027A1 (pl) 2012-04-27 2013-10-28 Instytut Farmaceutyczny Sposób otrzymywania N-[2-(dietylamino)etylo]-5-formylo-2,4-dimetylo-1H-pirolo-3-karboksyamidu o wysokiej czystosci i jego zastosowanie do wytwarzania sunitynibu
BR112014027128A2 (pt) 2012-05-04 2017-08-08 Pfizer antígenos associados à próstata e regimes de imunoterapia baseada em vacina
EP2849756A1 (en) 2012-05-16 2015-03-25 Novartis AG Dosage regimen for a pi-3 kinase inhibitor
SG11201408161RA (en) 2012-06-08 2015-01-29 Sutro Biopharma Inc Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
DK2863955T3 (en) 2012-06-26 2017-01-23 Sutro Biopharma Inc MODIFIED FC PROTEINS, INCLUDING LOCATION-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES THEREOF, METHODS OF PRODUCING ITS AND PROCEDURES FOR USE THEREOF
US20160009686A1 (en) 2012-08-17 2016-01-14 Cancer Therapeutics Crc Pty Limited Vegfr3 inhibitors
EP2887965A1 (en) 2012-08-22 2015-07-01 ImmunoGen, Inc. Cytotoxic benzodiazepine derivatives
HRP20190878T1 (hr) 2012-08-31 2019-07-26 Sutro Biopharma, Inc. Modificirane aminokiseline koje sadrže azidnu grupu
WO2014041349A1 (en) 2012-09-12 2014-03-20 Cancer Therapeutics Crc Pty Ltd Tetrahydropyran-4-ylethylamino- or tetrahydropyranyl-4-ethyloxy-pyrimidines or -pyridazines as isoprenylcysteincarboxymethyl transferase inhibitors
WO2014045101A1 (en) 2012-09-21 2014-03-27 Cellzome Gmbh Tetrazolo quinoxaline derivatives as tankyrase inhibitors
ES2644758T3 (es) 2012-10-16 2017-11-30 Tolero Pharmaceuticals, Inc. Moduladores de PKM2 y métodos para su uso
US9260426B2 (en) 2012-12-14 2016-02-16 Arrien Pharmaceuticals Llc Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
BR112015009004A8 (pt) 2012-12-21 2021-07-20 Eisai R&D Man Co Ltd forma amorfa de derivado de quinolina e método de produção da mesma
US9901647B2 (en) 2013-02-28 2018-02-27 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
WO2014134483A2 (en) 2013-02-28 2014-09-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
US20160031888A1 (en) * 2013-03-13 2016-02-04 Boston Biomedical, Inc. 3-(aryl or heteroaryl) methyleneindolin-2-one derivatives as inhibitors of cancer stem cell pathway kinases for the treatment of cancer
US10202356B2 (en) 2013-03-14 2019-02-12 Tolero Pharmaceuticals, Inc. JAK2 and ALK2 inhibitors and methods for their use
EP2968113B8 (en) 2013-03-14 2020-10-28 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
AR095443A1 (es) 2013-03-15 2015-10-14 Fundación Centro Nac De Investig Oncológicas Carlos Iii Heterociclos condensados con acción sobre atr
US9206188B2 (en) 2013-04-18 2015-12-08 Arrien Pharmaceuticals Llc Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors
CN104119321B (zh) * 2013-04-28 2017-09-08 齐鲁制药有限公司 二氢吲哚酮衍生物的二马来酸盐及其多晶型物
US10517861B2 (en) 2013-05-14 2019-12-31 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
WO2014194030A2 (en) 2013-05-31 2014-12-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
ES2658039T3 (es) 2013-07-10 2018-03-08 Sutro Biopharma, Inc. Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso
FR3008411B1 (fr) * 2013-07-12 2015-07-03 Servier Lab Nouveau sel de la 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione, sa preparation, et les formulations qui le contiennent
US11136625B2 (en) 2013-08-28 2021-10-05 Crown Bioscience, Inc. (Taicang) Gene expression signatures predictive of subject response to a multi-kinase inhibitor and methods of using the same
WO2015054658A1 (en) 2013-10-11 2015-04-16 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
US9278955B2 (en) 2013-10-18 2016-03-08 Sun Pharmaceutical Industries Limited Ascorbic acid salt of sunitinib
CA2838587A1 (en) 2013-10-18 2015-04-18 Hari Babu Matta Pure crystalline form ii of l-malic acid salt of sunitinib and processes for its preparation
SG10201910889VA (en) 2013-11-01 2020-01-30 Pfizer Vectors for expression of prostate-associated antigens
AU2014358773A1 (en) 2013-12-06 2016-06-02 Novartis Ag Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor
CN104829596B (zh) * 2014-02-10 2017-02-01 石家庄以岭药业股份有限公司 吡咯取代吲哚酮类衍生物、其制备方法、包含该衍生物的组合物、及其用途
CN103923014A (zh) * 2014-05-05 2014-07-16 宁夏宝马药业有限公司 环肌酸制备方法
EP3177289A4 (en) 2014-08-08 2018-03-21 Forsight Vision4, Inc. Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
KR102512940B1 (ko) 2014-08-28 2023-03-23 에자이 알앤드디 매니지먼트 가부시키가이샤 고순도의 퀴놀린 유도체 및 이를 제조하는 방법
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
JP6852848B2 (ja) 2015-01-13 2021-03-31 国立大学法人京都大学 筋萎縮性側索硬化症の予防及び／又は治療剤
LT3263106T (lt) 2015-02-25 2024-01-10 Eisai R&D Management Co., Ltd. Chinolino darinių kartumo sumažinimo būdas
KR102662228B1 (ko) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
EP3611506B1 (en) 2015-04-20 2021-11-17 Sumitomo Dainippon Pharma Oncology, Inc. Predicting response to alvocidib by mitochondrial profiling
WO2016184793A1 (en) 2015-05-15 2016-11-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for treating a patient with vegfr inhibitor-resistant metastatic renal cell carcinoma
JP6510075B2 (ja) 2015-05-18 2019-05-08 トレロ ファーマシューティカルズ， インコーポレイテッド バイオアベイラビリティが高いアルボシジブプロドラッグ
GB201510019D0 (en) 2015-06-09 2015-07-22 Cancer Therapeutics Crc Pty Ltd Compounds
WO2016204193A1 (ja) 2015-06-16 2016-12-22 株式会社ＰＲＩＳＭ Ｐｈａｒｍａ 抗がん剤
BR112018002427A8 (pt) 2015-08-03 2022-10-18 Tolero Pharmaceuticals Inc Uso de alvocidib e de azacitidina ou decitabina para tratar câncer e kit e composição farmacêutica contendo as ditas substâncias
KR102587702B1 (ko) 2015-08-20 2023-10-12 에자이 알앤드디 매니지먼트 가부시키가이샤 종양 치료제
MX2018003462A (es) 2015-09-22 2018-09-06 Graybug Vision Inc Compuestos y composiciones para el tratamiento de trastornos oculares.
GB2543550A (en) 2015-10-21 2017-04-26 Hox Therapeutics Ltd Peptides
AU2016347881A1 (en) 2015-11-02 2018-05-10 Novartis Ag Dosage regimen for a phosphatidylinositol 3-kinase inhibitor
KR20180102069A (ko) 2015-11-12 2018-09-14 그레이버그 비젼, 인크. 요법을 위한 응집성 마이크로입자
EP3407917A1 (en) 2016-01-27 2018-12-05 Sutro Biopharma, Inc. Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
EP3414330A4 (en) 2016-02-08 2019-07-03 Vitrisa Therapeutics, Inc. COMPOSITIONS WITH IMPROVED INTRAVITREAL HALF TIME AND USES THEREOF
EP3228630A1 (en) 2016-04-07 2017-10-11 IMBA-Institut für Molekulare Biotechnologie GmbH Combination of an apelin antagonist and an angiogenesis inhibitor for the treatment of cancer
CN107459519A (zh) 2016-06-06 2017-12-12 上海艾力斯医药科技有限公司 稠合嘧啶哌啶环衍生物及其制备方法和应用
CA3035081A1 (en) 2016-09-02 2018-03-08 Dana-Farber Cancer Institute, Inc. Composition and methods of treating b cell disorders
WO2018060833A1 (en) 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
SG11201903483VA (en) 2016-10-28 2019-05-30 Icahn School Med Mount Sinai Compositions and methods for treating ezh2-mediated cancer
US11279694B2 (en) 2016-11-18 2022-03-22 Sumitomo Dainippon Pharma Oncology, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
US10786502B2 (en) 2016-12-05 2020-09-29 Apros Therapeutics, Inc. Substituted pyrimidines containing acidic groups as TLR7 modulators
US10287253B2 (en) 2016-12-05 2019-05-14 Apros Therapeutics, Inc. Substituted pyrimidines containing acidic groups as TLR7 modulators
AU2017370694A1 (en) 2016-12-08 2019-07-25 Icahn School Of Medicine At Mount Sinai Compositions and methods for treating CDK4/6-mediated cancer
KR20190099260A (ko) 2016-12-19 2019-08-26 톨레로 파마수티컬스, 인크. 프로파일링 펩티드 및 감도 프로파일링을 위한 방법
AU2018219637B2 (en) 2017-02-08 2023-07-13 Eisai R&D Management Co., Ltd. Tumor-treating pharmaceutical composition
CN106916143B (zh) * 2017-03-14 2019-09-27 哈尔滨医科大学 一种预防和治疗冠心病的药物及其应用
CN110662543A (zh) 2017-03-23 2020-01-07 灰色视觉公司 用于治疗眼部疾病的药物和组合物
CA3057875A1 (en) 2017-05-10 2018-11-15 Graybug Vision, Inc. Extended release microparticles and suspensions thereof for medical therapy
MX2019013014A (es) 2017-05-16 2020-08-06 Eisai R&D Man Co Ltd Tratamiento de carcinoma hepatocelular.
WO2019023316A1 (en) 2017-07-26 2019-01-31 Sutro Biopharma, Inc. METHODS OF USING ANTI-CD74 ANTIBODIES AND ANTIBODY CONJUGATES IN THE TREATMENT OF A T CELL LYMPHOMA
US11497756B2 (en) 2017-09-12 2022-11-15 Sumitomo Pharma Oncology, Inc. Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib
SG11202002310UA (en) 2017-09-18 2020-04-29 Sutro Biopharma Inc Anti- folate receptor alpha antibody conjugates and their uses
US20200237766A1 (en) 2017-10-13 2020-07-30 Tolero Pharmaceuticals, Inc. Pkm2 activators in combination with reactive oxygen species for treatment of cancer
NL2019801B1 (en) 2017-10-25 2019-05-02 Univ Leiden Delivery vectors
EP3762381B1 (en) 2018-03-06 2025-05-07 Icahn School of Medicine at Mount Sinai Bivalent agents comprising a serine threonine kinase (akt) ligand covalently linked to a degradation/disruption moiety for the treatment of cancer
EP3539536A1 (en) 2018-03-15 2019-09-18 MH10 Spolka z ograniczona odpowiedzialnoscia A pharmaceutical composition of sunitinib or its salt thereof in its polymorphic form i
TW202003475A (zh) 2018-06-04 2020-01-16 美商亞博創新醫藥有限公司 含酸性基團之嘧啶化合物
GB201810092D0 (en) 2018-06-20 2018-08-08 Ctxt Pty Ltd Compounds
CN112996518A (zh) 2018-06-21 2021-06-18 西奈山伊坎医学院 Wd40重复结构域蛋白5(wdr5)降解/破坏化合物和使用方法
GB201810581D0 (en) 2018-06-28 2018-08-15 Ctxt Pty Ltd Compounds
AU2019310590A1 (en) 2018-07-26 2021-01-14 Sumitomo Pharma Oncology, Inc. Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same
JP2022500454A (ja) 2018-09-17 2022-01-04 ストロ バイオファーマ インコーポレーテッド 抗葉酸受容体抗体コンジュゲートによる併用療法
AU2019391097B2 (en) 2018-12-04 2025-07-03 Sumitomo Pharma Oncology, Inc. CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
KR20210107069A (ko) 2018-12-21 2021-08-31 다이이찌 산쿄 가부시키가이샤 항체-약물 컨쥬게이트와 키나아제 저해제의 조합
CN113412262A (zh) 2019-02-12 2021-09-17 大日本住友制药肿瘤公司 包含杂环蛋白激酶抑制剂的制剂
WO2020191326A1 (en) 2019-03-20 2020-09-24 Sumitomo Dainippon Pharma Oncology, Inc. Treatment of acute myeloid leukemia (aml) with venetoclax failure
MX2021009863A (es) 2019-03-21 2021-11-12 Onxeo Una molecula dbait en combinacion con inhibidor de quinasa para el tratamiento del cancer.
AU2020245437A1 (en) 2019-03-22 2021-09-30 Sumitomo Pharma Oncology, Inc. Compositions comprising PKM2 modulators and methods of treatment using the same
EP3958845A1 (en) 2019-04-25 2022-03-02 Synthon B.V. Pharmaceutical composition comprising amorphous sunitinib
WO2020227105A1 (en) 2019-05-03 2020-11-12 Sutro Biopharma, Inc. Anti-bcma antibody conjugates
CN114423463A (zh) * 2019-05-06 2022-04-29 西奈山伊坎医学院 作为hpk1的降解剂的异双功能化合物
AU2020335054A1 (en) 2019-08-31 2022-03-24 Etern Biopharma (Shanghai) Co., Ltd. Pyrazole derivative for FGFR inhibitor and preparation method therefor
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
EP4114852A1 (en) 2020-03-03 2023-01-11 Sutro Biopharma, Inc. Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
CN111233841A (zh) * 2020-03-17 2020-06-05 湖北扬信医药科技有限公司 一种舒尼替尼有关物质及其制备方法和用途
US12103924B2 (en) 2020-06-01 2024-10-01 Icahn School Of Medicine At Mount Sinai Mitogen-activated protein kinase kinase (MEK) degradation compounds and methods of use
JP7633786B2 (ja) 2020-09-18 2025-02-20 日本化薬株式会社 スニチニブリンゴ酸塩を有効成分とする医薬錠剤
WO2023278424A1 (en) * 2021-06-28 2023-01-05 The Regents Of The University Of California Methods for treating and ameliorating t cell related diseases
CN113717159A (zh) * 2021-09-16 2021-11-30 中国药科大学 吲哚酮类化合物及其药物组合物、制备方法及用途
JP2024540411A (ja) 2021-11-08 2024-10-31 プロジェントス・セラピューティクス・インコーポレイテッド 血小板由来成長因子受容体（ｐｄｇｆｒ）アルファ阻害剤及びその使用
EP4531927A1 (en) 2022-05-24 2025-04-09 Daiichi Sankyo Company, Limited Dosage regimen of an anti-cdh6 antibody-drug conjugate
EP4547284A1 (en) 2022-06-30 2025-05-07 Sutro Biopharma, Inc. Anti-ror1 antibodies and antibody conjugates, compositions comprising anti-ror1 antibodies or antibody conjugates, and methods of making and using anti-ror1 antibodies and antibody conjugates
WO2024017372A1 (zh) * 2022-07-22 2024-01-25 成都百裕制药股份有限公司 一种吲哚酮衍生物及其应用
CN118221652B (zh) * 2022-12-19 2025-06-06 沈阳药科大学 一种吲哚-2-酮衍生物及其制备方法和用途
WO2024188282A1 (zh) * 2023-03-14 2024-09-19 康百达（四川）生物医药科技有限公司 吲哚酮衍生物及其在医药上的应用
WO2025081117A2 (en) 2023-10-13 2025-04-17 Sutro Biopharma, Inc. Anti-tissue factor antibodies and antibody conjugates, compositions comprising anti-tissue factor antibodies or antibody conjugates, and methods of making and using anti-tissue factor antibodies and antibody conjugates

Family Cites Families (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL104796C (cs) 1957-08-19
DE878539C (de) 1939-08-17 1953-06-05 Hoechst Ag Verfahren zur Herstellung von Methinfarbstoffen
BE507136A (cs) 1950-11-18
BE553661A (cs) 1955-12-23
NL96047C (cs) 1956-06-08
NL251055A (cs) 1959-04-29
FR1398224A (fr) 1964-05-06 1965-05-07 Ici Ltd Procédé de teinture de matières textiles de polyacrylonitrile
US3308134A (en) 1965-10-22 1967-03-07 Mcneilab Inc Spiro(indan-2, 3'-indoline)-1, 2'-diones
US3551571A (en) 1967-05-19 1970-12-29 Endo Lab Methods for reducing pain,reducing fever and alleviating inflammatory syndromes with heteroaromatic pyrrol-3-yl ketones
US3564016A (en) 1968-03-07 1971-02-16 Endo Lab Method of decarbonylation
US4070366A (en) 1968-06-12 1978-01-24 Canadian Patents & Development Limited Alkylation process
FR1599772A (cs) 1968-09-17 1970-07-20
US3922163A (en) 1970-01-30 1975-11-25 Upjohn Co Organic compounds and process
US3715364A (en) 1970-12-28 1973-02-06 Merck & Co Inc Nitroimidazole carboxamides
DE2159362A1 (de) 1971-11-30 1973-06-14 Bayer Ag Nitrofuranderivate, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
DE2159360A1 (de) 1971-11-30 1973-06-14 Bayer Ag Nitrofuranderivate, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
DE2159361A1 (de) 1971-11-30 1973-06-14 Bayer Ag Nitrofuranderivate, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
DE2159363A1 (de) 1971-11-30 1973-06-14 Bayer Ag Antimikrobielle mittel
GB1384599A (en) 1972-05-04 1975-02-19 Colgate Palmolive Co Coloured detergent compositions
US3880871A (en) 1973-09-27 1975-04-29 Squibb & Sons Inc Isothiocyanophenyl substituted imidazoles
US4002643A (en) 1975-06-27 1977-01-11 Mcneil Laboratories, Inc. Preparation of β-acyl pyrroles
US4002749A (en) 1975-08-12 1977-01-11 E. R. Squibb & Sons, Inc. Substituted indolinones
US4053613A (en) 1975-09-17 1977-10-11 E. R. Squibb & Sons, Inc. 1,3,thiazolinyl and 1,3 thiazinyl substituted indolinones
DE2855306A1 (de) 1978-12-21 1980-07-10 Boehringer Sohn Ingelheim Mittel zur senkung der herzfrequenz
GR73560B (cs) 1979-02-24 1984-03-15 Pfizer
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4343923A (en) 1980-08-07 1982-08-10 Armstrong World Industries, Inc. Process for reducing the acid dye uptake of polyamide textile materials with N-acylimidazole compound
CH646956A5 (de) 1981-12-15 1984-12-28 Ciba Geigy Ag Imidazolide.
EP0095285A1 (en) 1982-05-21 1983-11-30 Sumitomo Chemical Company, Limited N-acylimidazoles, their production and use
US4493642A (en) 1982-12-27 1985-01-15 Bogdon Glendon J Orthodontic device and associated orthodontic method
DE3310891A1 (de) 1983-03-25 1984-09-27 Boehringer Mannheim Gmbh, 6800 Mannheim Neue indolinon-(2)-derivate, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und zwischenprodukte
US4489089A (en) 1983-04-06 1984-12-18 American Cyanamid Company Substituted N-[ω-(1H-imidazol-1-yl)alkyl]-amides
EP0124482B1 (de) 1983-04-29 1989-11-08 Ciba-Geigy Ag Neue Imidazolide und deren Verwendung als Härter für Polyepoxidverbindungen
DE3415138A1 (de) 1984-04-21 1985-10-31 Basf Ag, 6700 Ludwigshafen N-(azolylcarbamoyl)-hydroxylamine und diese enthaltende fungizide
DE3426419A1 (de) 1984-07-18 1986-01-23 Boehringer Mannheim Gmbh, 6800 Mannheim Neue oxindol-derivate, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und zwischenprodukte
US4560700A (en) 1985-02-08 1985-12-24 Merrell Dow Pharmaceuticals Inc. Pyrrole-3-carboxylate cardiotonic agents
JPH078851B2 (ja) 1985-07-29 1995-02-01 鐘淵化学工業株式会社 ３−フエニルチオメチルスチレン誘導体
JPS6229570A (ja) 1985-07-29 1987-02-07 Kanegafuchi Chem Ind Co Ltd ３，５−ジイソプロピルベンジリデン複素環式化合物
JPS6239564A (ja) 1985-08-13 1987-02-20 Kanegafuchi Chem Ind Co Ltd α−ベンジリデン−γ−ブチロラクトンまたはγ−ブチロラクタム誘導体
US4966849A (en) 1985-09-20 1990-10-30 President And Fellows Of Harvard College CDNA and genes for human angiogenin (angiogenesis factor) and methods of expression
WO1993012786A1 (en) 1986-07-10 1993-07-08 Howard Harry R Jr Indolinone derivatives
US4853404A (en) 1986-10-13 1989-08-01 Tanabe Seiyaku Co., Ltd. Phenoxyacetic acid derivatives composition and use
JPS63141955A (ja) 1986-12-03 1988-06-14 Kanegafuchi Chem Ind Co Ltd トリベンジルアミン誘導体
US5089516A (en) 1987-03-11 1992-02-18 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha 1-phenyl-3,5-pyrazolidinedione hydroxystyrene compounds which have tyrosine kinase inhibiting activity
US5202341A (en) 1987-03-11 1993-04-13 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Hydroxystyrene compounds having tyrosine kinase inhibiting activity
WO1988007035A1 (en) 1987-03-11 1988-09-22 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Hydroxystyrene derivatives
US5043348A (en) 1987-04-24 1991-08-27 Cassella Aktiengesellschaft Pyrrolealdehydes, their preparation and their use
US5217999A (en) 1987-12-24 1993-06-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Styryl compounds which inhibit EGF receptor protein tyrosine kinase
DE3808071A1 (de) 1988-03-11 1989-09-21 Basf Ag Verfahren zur herstellung von acylierten imidazolen
US4868304A (en) 1988-05-27 1989-09-19 Iowa State University Research Foundation, Inc. Synthesis of nitrogen heterocycles
CA1339784C (en) 1988-06-23 1998-03-31 Shinya Inoue Pyrrolecarboxylic acid derivatives
JPH06104658B2 (ja) 1988-06-23 1994-12-21 三菱化成株式会社 ピロールカルボン酸誘導体
GB8816944D0 (en) 1988-07-15 1988-08-17 Sobio Lab Compounds
DE3824658A1 (de) 1988-07-15 1990-01-18 Schering Ag N-hetaryl-imidazolderivate
US5084280A (en) 1988-12-15 1992-01-28 Chapman Chemical Company Wood preservation composition and method
DE3902439A1 (de) 1989-01-27 1990-08-02 Basf Ag Pflanzenschuetzende mittel auf basis von 1-aryl- bzw. 1-hetarylimidazolcarbonsaeureestern
US5047554A (en) 1989-04-18 1991-09-10 Pfizer Inc. 3-substituted-2-oxindole derivatives
DE69031649T2 (de) 1989-07-25 1998-02-26 Taiho Pharmaceutical Co Ltd Oxoindolderivate
US5258357A (en) 1989-10-07 1993-11-02 Basf Aktiengesellschaft Carboxamides, their preparation and their use as herbicides
CA2032421A1 (en) 1989-12-20 1991-06-21 Mitsubishi Chemical Corporation Pyrrolealdehyde derivative
GB9004483D0 (en) 1990-02-28 1990-04-25 Erba Carlo Spa New aryl-and heteroarylethenylene derivatives and process for their preparation
CA2012634A1 (en) 1990-03-20 1991-09-20 Hassan Salari Tyrphostins for treatment of allergic, inflammatory and cardiovascular diseases
CA2078214C (en) 1990-04-02 1995-03-28 Robert Lee Dow Benzylphosphonic acid tyrosine kinase inhibitors
US5196446A (en) 1990-04-16 1993-03-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Certain indole compounds which inhibit EGF receptor tyrosine kinase
US5302606A (en) 1990-04-16 1994-04-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase
JP2944721B2 (ja) 1990-08-22 1999-09-06 生化学工業株式会社 エンドトキシンの測定剤
WO1992007830A2 (en) 1990-10-29 1992-05-14 Pfizer Inc. Oxindole peptide antagonists
IT1247509B (it) 1991-04-19 1994-12-17 Univ Cagliari Composti di sintesi atti all'impiego nella terapia delle infezioni da rhinovirus
AU658646B2 (en) 1991-05-10 1995-04-27 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
CA2108889A1 (en) 1991-05-29 1992-11-30 Robert Lee Dow Tricyclic polyhydroxylic tyrosine kinase inhibitors
GB9115160D0 (en) 1991-07-12 1991-08-28 Erba Carlo Spa Methylen-oxindole derivatives and process for their preparation
US5124347A (en) 1991-07-31 1992-06-23 Warner-Lambert Co. 3-5-ditertiarybutylphenyl-4-hydroxymethylidene derivatives of 1,3-dihydro-2H-indole-2-ones as antiinflammatory agents
JPH0558894A (ja) 1991-08-27 1993-03-09 Kanegafuchi Chem Ind Co Ltd 抗腫瘍剤
HU219131B (hu) 1991-10-18 2001-02-28 Monsanto Co. Módszer és fungicid készítmény növények torsgombabetegségének gátlására és a hatóanyagok
US5389661A (en) 1991-12-05 1995-02-14 Warner-Lambert Company Imidazole and 1,2,4-triazole derivatives with angiotensin II antagonist properties
US5322950A (en) 1991-12-05 1994-06-21 Warner-Lambert Company Imidazole with angiotensin II antagonist properties
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
FR2689397A1 (fr) 1992-04-01 1993-10-08 Adir Utilisation des dérivés de la 3-(3,5-Ditert-Butyl-4-Hydroxybenzylidenyl) Indoline-2-one pour l'obtention de médicaments.
DE4211531A1 (de) 1992-04-06 1993-10-07 Cassella Ag Verfahren zur Herstellung von Pyrrolderivaten
ATE195530T1 (de) 1992-05-20 2000-09-15 Merck & Co Inc 17-ether und thioether von 4-aza-steroiden
FR2694004B1 (fr) 1992-07-21 1994-08-26 Adir Nouvelles 3-(Hydroxybenzylidényl)-indoline-2-ones et 3-(hydroxybenzylidényl)-indoline-2-thiones, leurs procédés de préparation, et les compositions pharmaceutiques qui les contiennent.
EP0654024A1 (en) 1992-08-06 1995-05-24 Warner-Lambert Company 2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and which have antitumor properties
US5565324A (en) 1992-10-01 1996-10-15 The Trustees Of Columbia University In The City Of New York Complex combinatorial chemical libraries encoded with tags
US5330992A (en) 1992-10-23 1994-07-19 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolinones
FI951987A7 (fi) 1992-10-28 1995-04-26 Genentech Inc Verisuoniin liittyvien endoteliaaliseen solukasvutekijän antagonistit
GB9226855D0 (en) 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
JP3507124B2 (ja) 1993-05-26 2004-03-15 塩野義製薬株式会社 ベンジリデン誘導体の製造法
EP0632102B1 (de) 1993-06-28 1997-04-02 Bayer Ag Massefärben von Kunststoffen
GB9313638D0 (en) 1993-07-01 1993-08-18 Erba Carlo Spa Arylidene and heteroarylidene oxindole derivatives and process for their preparation
US5332736A (en) 1993-11-01 1994-07-26 Ortho Pharmaceutical Corporation Anti-convulsant aroyl aminoacylpyrroles
US5502072A (en) 1993-11-26 1996-03-26 Pfizer Inc. Substituted oxindoles
GB9326136D0 (en) 1993-12-22 1994-02-23 Erba Carlo Spa Biologically active 3-substituted oxindole derivatives useful as anti-angiogenic agents
US5610173A (en) 1994-01-07 1997-03-11 Sugen, Inc. Formulations for lipophilic compounds
AU2096895A (en) 1994-03-07 1995-09-25 Sugen, Incorporated Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
GB9412719D0 (en) 1994-06-24 1994-08-17 Erba Carlo Spa Substituted azaindolylidene compounds and process for their preparation
GB9423997D0 (en) 1994-11-28 1995-01-11 Erba Carlo Spa Substituted 3-arylidene-7-azaoxindole compounds and process for their preparation
GB9501567D0 (en) 1995-01-26 1995-03-15 Pharmacia Spa Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors
GB9507298D0 (en) 1995-04-07 1995-05-31 Pharmacia Spa Substituted indolylmethylene-oxindale analogues as tyrosine kinase inhibitors
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US5786488A (en) 1996-11-13 1998-07-28 Sugen, Inc. Synthetic methods for the preparation of indolyquinones
JP3246712B2 (ja) 1995-11-15 2002-01-15 株式会社トクヤマ エテニルアミド化合物の製造方法
AU708167B2 (en) 1996-01-17 1999-07-29 Taiho Pharmaceutical Co., Ltd. Intimal hypertrophy inhibitors
EP0788890A1 (en) 1996-02-06 1997-08-13 Agfa-Gevaert N.V. Dyes and dye-donor elements for thermal dye transfer recording
WO1997034920A1 (en) 1996-03-21 1997-09-25 Sugen, Inc. Assays for kdr/flk-1 receptor tyrosine kinase inhibitors
SK131498A3 (en) 1996-03-29 2000-09-12 Pfizer BENZYL(IDENE)-LACTAM DERIVATIVES, THEIR PREPARATION AND THEIR USEì (54) AS SELECTIVE (ANT)AGONISTS OF 5-HT1A- AND/OR 5-HT1D
CA2206201A1 (en) 1996-05-29 1997-11-29 Yoshiaki Isobe Pyrazole derivatives and their pharmaceutical use
ES2208935T3 (es) 1996-08-01 2004-06-16 Merckle Gmbh Acidos acil-pirrol-dicarboxilicos y acidos acil-indol-dicarboxilicos, asi como sus derivados como inhibidores de la fosfolipasa a2 citosolica.
EP0931152A2 (en) 1996-08-21 1999-07-28 Sugen, Inc. Crystal structures of a protein tyrosine kinase
CA2264220A1 (en) 1996-08-23 1998-02-26 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease
WO1998024432A2 (en) 1996-12-05 1998-06-11 Sugen, Inc. Use of indolinone compounds as modulators of protein kinases
CO4940469A1 (es) 1997-03-05 2000-07-24 Sugen Inc Composicion oral de estabilidad mejorada que comprende un derivado de indolinona y una mezcla de gliceridos o esteres de polietilenglicol
AU6887698A (en) 1997-04-08 1998-10-30 Sugen, Inc. Study and treatment of diseases related to specific cellular functions of receptor protein tyrosine kinases
ES2239393T3 (es) * 1997-05-07 2005-09-16 Sugen, Inc. Derivados de 2-indolinona utilizados como moduladores de la actividad de la proteina-quinasa.
JP2002512628A (ja) 1997-06-13 2002-04-23 スージェン・インコーポレーテッド タンパク質チロシン酵素関連の細胞信号伝達を調節するための新規ヘテロアリール化合物
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6133305A (en) 1997-09-26 2000-10-17 Sugen, Inc. 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
UA58476C2 (uk) 1997-10-09 2003-08-15 Санофі-Сентелябо Похідні 8-азабіцикло[3.2.1]октан-3-метанаміну, фармацевтична композиція та лікарський засіб
WO2000008202A2 (en) 1998-08-04 2000-02-17 Sugen, Inc. 3-methylidenyl-2-indolinone modulators of protein kinase
EP1066257A2 (en) 1998-03-26 2001-01-10 Sugen, Inc. Heterocylic classes of compounds for the modulating tyrosine protein kinase
DE19816624A1 (de) 1998-04-15 1999-10-21 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
IL139934A0 (en) * 1998-05-29 2002-02-10 Sugen Inc Pyrrole substituted 2-indolinone derivatives and pharmaceutical compositions containing the same
DE19826940A1 (de) 1998-06-17 1999-12-23 Bayer Ag Substituierte N-Aryl-O-alkyl-carbamate
US6462072B1 (en) 1998-09-21 2002-10-08 Gpi Nil Holdings, Inc. Cyclic ester or amide derivatives
CZ20012113A3 (cs) 1998-12-14 2001-11-14 Cellegy Pharmaceuticals, Inc. Prostředky a způsoby pro léčbu onemocnění anorektální oblasti
BR9916327A (pt) * 1998-12-17 2001-09-18 Hoffmann La Roche Oxindóis de 4-alquenila (e alquinila) como inibidores de cinases dependentes de ciclina, em particular, cdk2
US6284894B1 (en) 1998-12-18 2001-09-04 Nycomed Imaging As Preparation of allylic aromatic compounds
IL143920A0 (en) * 1998-12-31 2002-04-21 Sugen Inc 3-heteroarylidenyl-2-indolinone derivatives and pharmaceutical compositions containing the same
CA2368041A1 (en) 1999-03-24 2000-09-28 Sugen, Inc. Indolinone compounds as kinase inhibitors
WO2001037820A2 (en) * 1999-11-24 2001-05-31 Sugen, Inc. Ionizable indolinone derivatives and their use as ptk ligands
AU784266B2 (en) * 1999-12-22 2006-03-02 Sugen, Inc. Indolinone derivatives for modulation of c-kit tyrosine kinase
DK1255752T3 (da) * 2000-02-15 2007-11-26 Sugen Inc Pyrrolsubstituerede 2-indolinonproteinkinaseinhibitorer
TWI270545B (en) 2000-05-24 2007-01-11 Sugen Inc Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
US6635640B2 (en) * 2000-06-30 2003-10-21 Sugen, Inc. 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
WO2002055517A2 (en) * 2000-12-20 2002-07-18 Jingrong Cui 4-(hetero)aryl substituted indolinones

Also Published As

Publication number Publication date
FR08C0002I2 (fr) 2009-01-02
NL300332I2 (nl) 2008-04-01
MXPA02008021A (es) 2004-04-05
BRPI0108394B1 (pt) 2018-12-11
EA200200862A1 (ru) 2003-02-27
ME00415B (me) 2011-10-10
CY2010004I2 (el) 2012-01-25
US7125905B2 (en) 2006-10-24
HRP20020751B1 (hr) 2011-01-31
CN1439005A (zh) 2003-08-27
CA2399358C (en) 2006-03-21
CR20120007A (es) 2012-02-24
US6573293B2 (en) 2003-06-03
SK13262002A3 (sk) 2003-03-04
PL211834B1 (pl) 2012-06-29
IS6501A (is) 2002-08-13
US20040063773A1 (en) 2004-04-01
MY130363A (en) 2007-06-29
NO2010002I2 (no) 2010-12-06
HK1051188A1 (en) 2003-07-25
NO20023831L (no) 2002-10-15
YU61402A (sh) 2005-07-19
NL300332I1 (nl) 2008-03-03
NO20023831D0 (no) 2002-08-13
KR20030003229A (ko) 2003-01-09
FR08C0002I1 (cs) 2008-03-21
US7572924B2 (en) 2009-08-11
FR10C0003I2 (fr) 2012-06-22
LU91657I2 (fr) 2010-05-03
SI1255752T1 (sl) 2007-12-31
LTC1255752I2 (lt) 2019-08-26
HU228979B1 (en) 2013-07-29
NL300430I1 (nl) 2010-03-01
DE60129794D1 (de) 2007-09-20
TWI306860B (en) 2009-03-01
CN1329390C (zh) 2007-08-01
JP2003523340A (ja) 2003-08-05
BG107078A (bg) 2003-04-30
BRPI0117360B1 (pt) 2018-11-13
IS2491B (is) 2009-01-15
DE122010000004I1 (de) 2010-04-15
AU2001239770B2 (en) 2006-01-05
NZ520640A (en) 2005-04-29
FR10C0003I1 (fr) 2010-03-05
HRP20020751A2 (en) 2004-12-31
CO5280092A1 (es) 2003-05-30
NO2008019I2 (no) 2011-10-17
WO2001060814A3 (en) 2002-01-24
LTPA2008002I1 (lt) 2019-02-25
NO2019005I1 (no) 2019-02-11
EP1255752A2 (en) 2002-11-13
ATE369359T1 (de) 2007-08-15
RS50444B (sr) 2010-03-02
PL361209A1 (en) 2004-09-20
UA73976C2 (uk) 2005-10-17
US20020156292A1 (en) 2002-10-24
BRPI0108394B8 (pt) 2021-05-25
CZ20023081A3 (cs) 2003-02-12
LU91407I9 (cs) 2018-12-28
CY2010004I1 (el) 2012-01-25
DK1255752T3 (da) 2007-11-26
HUP0204433A2 (hu) 2003-04-28
IL151127A0 (en) 2003-04-10
CA2399358A1 (en) 2001-08-23
BRPI0117360A2 (pt) 2012-01-24
HUP0204433A3 (en) 2007-08-28
ES2290117T3 (es) 2008-02-16
DE60129794T2 (de) 2007-12-06
BR0108394A (pt) 2004-06-22
WO2001060814A2 (en) 2001-08-23
EA005996B1 (ru) 2005-08-25
DE122008000002I1 (de) 2008-04-17
KR100713960B1 (ko) 2007-05-02
CY2008004I1 (el) 2009-11-04
SK287142B6 (sk) 2010-01-07
CY2008004I2 (el) 2009-11-04
BE2010C009I2 (cs) 2020-01-30
NL300430I2 (nl) 2010-04-01
PE20011083A1 (es) 2001-10-26
BRPI0117360B8 (pt) 2021-07-06
LU91407I2 (fr) 2008-03-10
AU3977001A (en) 2001-08-27
PT1255752E (pt) 2007-10-17
US20070010569A1 (en) 2007-01-11
BG65764B1 (bg) 2009-10-30
NO2008019I1 (no) 2009-01-12
CY1108032T1 (el) 2011-04-06
US20050176802A1 (en) 2005-08-11
AR034118A1 (es) 2004-02-04
JP3663382B2 (ja) 2005-06-22
NO2010002I1 (no) 2010-03-08
CR20120009A (es) 2012-02-07
EP1255752B1 (en) 2007-08-08
CZ303705B6 (cs) 2013-03-27

Similar Documents

Publication Publication Date Title
NO325532B1 (no) Pyrrolsubstituerte 2-indolinoner, farmasoytisk preparat omfattende slike, fremgangsmate for a modulere den katalytiske aktiviteten til en proteinkinase in vitro basert pa bruk av slike forbindelser, samt anvendelse av slike forbindelser til fremstilling av medikamenter for behandling av sykdommer.
EP1370554B1 (en) 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone derivatives as protein kinase inhibitors
US6635640B2 (en) 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
US20040138269A1 (en) Substituted pyrroles as kinase inhibitors
AU2001239770A1 (en) Pyrrole substituted 2-indolinone protein kinase inhibitors
NO318083B1 (no) Pyrrolsubstituert 2-indolinon protein kinase inhibitorer
US6797725B2 (en) Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
US7214700B2 (en) (2-Oxindol-3-ylidenyl) acetic acid derivatives and their use as protein kinase inhibitors
HK1051188B (en) Pyrrole substituted 2-indolinone protein kinase inhibitors
HK1059621B (en) 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone derivatives as protein kinase inhibitors

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: BRYN AARFLOT AS POSTBOKS 449 SENTRUM OSLO, 0104 NO

SPCF Filing of supplementary protection certificate

Free format text: PRODUCT NAME: PALLADIA - TOCERANIB; NAT. REG. NO/DATE: EU/2/09/100/001-3/NO 20091029; FIRST REG. NO/DATE: EU/2/09/100/001-003 20090923

Spc suppl protection certif: 2010002

Filing date: 20100209

SPCG Granted supplementary protection certificate

Free format text: PRODUCT NAME: PALLADIA - TOCERANIB; NAT. REG. NO/DATE: EU/2/09/100/001-3/NO 20091029; FIRST REG. NO/DATE: EU/2/09/100/001-003 20090923

Spc suppl protection certif: 2010002

Filing date: 20100209

Extension date: 20240923

SPCG Granted supplementary protection certificate

Free format text: PRODUCT NAME: SUTENT - SUNITINIB; NAT. REG. NO/DATE: EU106347001-003 20060727; FIRST REG. NO/DATE: EU , EU106347001-003 20060719

Spc suppl protection certif: 2008019

Filing date: 20081208

Extension date: 20210719

SPCF Filing of supplementary protection certificate

Free format text: PRODUCT NAME: N-[2-(DIETYLAMINO)ETYL]-5-[(Z)-(5-FLUORO-2-OKSO-1,2-DIHYDRO-3H-INDOL-3-YLIDEN)METYL]-2,4-DIMETYL-1H-PYRROL-3-KARBOKSAMID (SUNITINIB), SAMT FARMASOEYTISK AKSEPTABLE SALTER; NAT. REG. NO/DATE: NO , 2008019 20081208

Spc suppl protection certif: 2019005

Filing date: 20190205

SPCG Granted supplementary protection certificate

Free format text: PRODUCT NAME: N-(2-(DIETYLAMINO)ETYL)-5-((Z)-; REG. NO/DATE: 2008019 20081208

Spc suppl protection certif: 2019005

Filing date: 20190205

Extension date: 20220124

SPCG Granted supplementary protection certificate

Free format text: PRODUCT NAME: N-(2-(DIETYLAMINO)ETYL)-5-((Z)-; REG. NO/DATE: 2008019 20081208

Spc suppl protection certif: 2019005

Filing date: 20190205

Extension date: 20220124

MK1K Patent expired
SPCX Expiry of an spc

Spc suppl protection certif: 2019005

SPCX Expiry of an spc

Spc suppl protection certif: 2008019